Stocktoria
Nexalin Technology, Inc. NXL
Nexalin Technology, Inc. (NXL) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $301,647 at a -2725.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NXL | Nexalin Technology, Inc. | 4/9 | — | — | — |
| POSC | POSITRON CORP | 2/9 | — | — | — |
| ENDV | ENDONOVO THERAPEUTICS, INC. | 3/9 | — | — | — |
| ITOC | iTonic Holdings Ltd | 1/9 | 5.57 | — | — |
| VANI | Vivani Medical, Inc. | 1/9 | -14.41 | — | — |
| GTHP | GUIDED THERAPEUTICS INC | 3/9 | — | — | — |
| HCIL | Hongchang International Co., Ltd | 2/9 | 2.23 | — | — |
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
FAQ
Is NXL financially healthy?
Nexalin Technology, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does NXL pay a dividend?
No, Nexalin Technology, Inc. does not currently pay a dividend.
How profitable is NXL?
In FY2025, Nexalin Technology, Inc. had a net margin of -2725.8% and a return on equity of -219.4%.
What is the analyst price target for NXL?
The average Wall-Street price target for Nexalin Technology, Inc. is $2.00, about 462.6% above the recent price, from 1 analysts.
Is NXL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Nexalin Technology, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.